Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer

This study is testing a new thermosensitive embolic agent — a substance injected through a blood vessel into a liver tumor to block its blood supply and deliver chemotherapy — during a procedure called TACE (transarterial chemoembolization) for primary liver cancer. Researchers want to see if this new agent is safer and more effective than existing options. **You may be eligible if:** - You are aged 18 to 80 and have been diagnosed with primary liver cancer (hepatocellular carcinoma) - Your cancer requires TACE treatment based on Chinese liver cancer staging guidelines - You have at least one untreated liver tumor up to 10 cm in size that meets standard measurement criteria - You are willing to participate and provide written consent **You may NOT be eligible if:** - Your target tumor has already been treated with surgery, TACE, radiation, or ablation - Your blood counts are too low to safely proceed - You have significant kidney dysfunction or uncorrectable blood clotting problems - The main portal vein (blood vessel to the liver) is completely blocked - You have known allergies to the study drugs, contrast dye, or embolic materials - You are currently using heart rhythm medications called cardiac glycosides - You are pregnant, breastfeeding, or planning to become pregnant - You have other serious cancer spread throughout the body with a life expectancy of less than 90 days Talk to your doctor to see if this trial is right for you.